MELPIDA is a gene therapy product being developed for the treatment of Spastic Paraplegia Type 50 (SPG50), which is one of a group of four genetic disorders (SPG47, SPG50, SPG51 and SPG52) comprising AP-4 related Spastic Paraplegia (AP4-SPG). Inherited in an autosomal recessive pattern, AP-4- SPG is caused by biallelic pathogenic variants in one of 4 genes that encode components of the heterotrimeric adaptor protein complex 4 (AP4). Mutations in any of the components result in disrupted AP-4 function, and result in a common, shared clinical phenotype. Adaptor protein complexes such as AP-4 play key roles in signal-mediated trafficking of integral membrane proteins. They mediate vesicle formation and the cargo contained within these vesicles. While the precise function of the AP-4 complex is not fully understood, recent data suggests it plays an important role in protein sorting through the golgi, including regulation of trafficking of components required for autophagy. Deficiency in AP-4 leads to progressive neurodegeneration.~AP-4-HSP is an ultra-rare autosomal recessive disease with ~156 patients identified worldwide, 59 of which have the SPG50 subtype. There are approximately 9 patients with SPG50 in North America (OMIM #612936), ClinicalTrials.gov Identifier: NCT04712812. SPG50 is caused by biallelic pathogenic variants in the AP4M1 gene.~The AP4-deficiency syndrome (AP-4-HSP) is characterized by progressive spasticity, microcephaly, intellectual deficiency, dysmorphic traits, and growth retardation. Symptoms of AP-4-HSP begin in infancy, though patients are often not correctly identified and diagnosed until age 5 to 10 years. Patients experience progressive spastic paraplegia in the first decade of life, resulting in quadriplegia by adolescence or early adulthood with associated wheelchair dependence. There is also the presence of severe, progressive cognitive impairment. Epilepsy is an important co-morbidity present in the majority of cases. Only a few affected individuals have been identified to survive beyond age 30 year, though the extent of early mortality is yet to be fully elucidated.~Based on an AP-4-HSP natural history study currently in progress at Boston Children's Hospital (BCH), it is evident that disease severity ranges from child to child, but that most children fall into the severely affected (i.e. severe spasticity with paralysis and severe cognitive impairment) category. A small proportion of children, considered least severe, are able to speak in short sentences, walk with an abnormal gait, and have few to no seizures early on in the disease (less than 10 years of age). However, most children in this less severe category still experience progressive decline, ultimately losing the ability to walk and becoming quadriplegic between the ages of 10 and 20 years.~The majority of children with the SPG50 subtype of AP-4-HSP conform to a severe presentation, and are completely non-verbal, have microcephaly, never walk, have epilepsy and are severely cognitively impaired by the age of 10. It is not known how patients are affected later in life as very few have been identified beyond the age of 30. SPG50 is thus a degenerative neurological disease, affecting both cognitive and motor capabilities. Importantly, there is significant care giver burden, as all patients eventually require complete support for all activities of daily living from family and/or caregivers. There are no treatments currently available for patients with SPG50.
MELPIDA is proposed for the treatment of subjects with SPG50 and targets neuronal cells to deliver a fully functional human AP4M1 cDNA copy via intrathecal injection to counter the associated neuronal loss. Outcomes will evaluate the safety and tolerability of a single dose of MELPIDA, which will be measured by the treatment-associated adverse events (AEs) and serious adverse events (SAEs). Secondarily, the trial will explore efficacy in terms of disease burden assessments.